JP2010532381A - Ｒａｆキナーゼ阻害剤として有用な複素環式化合物 - Google Patents

Ｒａｆキナーゼ阻害剤として有用な複素環式化合物 Download PDF

Info

Publication number
JP2010532381A
JP2010532381A JP2010515223A JP2010515223A JP2010532381A JP 2010532381 A JP2010532381 A JP 2010532381A JP 2010515223 A JP2010515223 A JP 2010515223A JP 2010515223 A JP2010515223 A JP 2010515223A JP 2010532381 A JP2010532381 A JP 2010532381A
Authority
JP
Japan
Prior art keywords
compound
optionally substituted
mmol
nitrogen
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010515223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010532381A5 (cg-RX-API-DMAC7.html
Inventor
ジェニファー コスロー，
ビン グアン，
アレクセイ イシチェンコ，
ジョン ホワード ジョーンズ，
グナナサンバンダム クマールエーベル，
アレクセイ ルゴフスコイ，
ハイルー ペン，
ノエル ポーウェル，
ブライアン レイムンド，
裕子 田中
ジェフリー ベッセルズ，
トーマス ウィン，
チリ シン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Inc
Biogen Idec Inc
Biogen Idec MA Inc
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Biogen Idec Inc, Biogen Idec MA Inc, Biogen MA Inc filed Critical Biogen Inc
Publication of JP2010532381A publication Critical patent/JP2010532381A/ja
Publication of JP2010532381A5 publication Critical patent/JP2010532381A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2010515223A 2007-06-29 2008-06-30 Ｒａｆキナーゼ阻害剤として有用な複素環式化合物 Pending JP2010532381A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94731907P 2007-06-29 2007-06-29
PCT/US2008/068789 WO2009006404A2 (en) 2007-06-29 2008-06-30 Heterocyclic compounds useful as raf kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2010532381A true JP2010532381A (ja) 2010-10-07
JP2010532381A5 JP2010532381A5 (cg-RX-API-DMAC7.html) 2012-07-26

Family

ID=40015666

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010515223A Pending JP2010532381A (ja) 2007-06-29 2008-06-30 Ｒａｆキナーゼ阻害剤として有用な複素環式化合物

Country Status (8)

Country Link
US (1) US7968536B2 (cg-RX-API-DMAC7.html)
EP (1) EP2167497A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010532381A (cg-RX-API-DMAC7.html)
CN (1) CN101743242A (cg-RX-API-DMAC7.html)
AU (1) AU2008273017C1 (cg-RX-API-DMAC7.html)
CA (1) CA2694284A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ582349A (cg-RX-API-DMAC7.html)
WO (1) WO2009006404A2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106898779A (zh) * 2015-12-21 2017-06-27 斯沃奇集团研究和开发有限公司 用于金属/空气电池的正极和制造该正极的方法
JP2021512861A (ja) * 2018-02-01 2021-05-20 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
JP2023517519A (ja) * 2020-03-02 2023-04-26 シロナックス・リミテッド フェロトーシス阻害剤ジアリールアミンパラアセトアミド類

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
KR20110060904A (ko) * 2008-09-26 2011-06-08 베링거 인겔하임 인터내셔날 게엠베하 Ｃｃｒ1 수용체 길항제로서의 아자인다졸 화합물
CA2748274A1 (en) * 2008-12-30 2010-07-08 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as raf kinase inhibitors
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
ES2549502T3 (es) 2009-11-20 2015-10-28 Sk Chemicals Co., Ltd. Antagonistas de receptores de gonadoliberina, método de fabricación de los mismos, y composición farmacéutica que los contienen
WO2012142029A2 (en) 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
JP2015508752A (ja) 2012-02-03 2015-03-23 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 殺菌性ピリミジン化合物
EP2825533B1 (en) 2012-03-13 2016-10-19 Basf Se Fungicidal pyrimidine compounds
CN102936251A (zh) * 2012-11-05 2013-02-20 上海毕得医药科技有限公司 一种吡咯并[2,3-d]嘧啶衍生物的制备方法
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
CN105722833A (zh) 2013-09-16 2016-06-29 巴斯夫欧洲公司 杀真菌的嘧啶化合物
CN104761502A (zh) * 2014-01-03 2015-07-08 中国药科大学 苯并咪唑衍生物、其制法及医药用途
US9914698B2 (en) 2014-01-08 2018-03-13 Shanghai Jiaotong University School Of Medicine Stearoyl amino acid salt and preparation method and application thereof
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN106663839B (zh) * 2015-01-14 2019-05-10 株式会社东芝 非水电解质电池和电池组
JP2019196307A (ja) * 2016-09-15 2019-11-14 武田薬品工業株式会社 複素環アミド化合物
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
CN106928152A (zh) * 2017-03-03 2017-07-07 符爱清 一种尿嘧啶的制备方法
DK3618875T3 (da) 2017-05-02 2023-07-10 Novartis Ag Kombinationsterapi omfattende en raf-inhibitor og trametinib
AU2018276192B2 (en) 2017-05-30 2022-05-19 Dot Therapeutics-1, Inc. Method for producing optically active compound
WO2019067623A1 (en) * 2017-09-27 2019-04-04 The Regents Of The University Of California POWERFUL ANTIVIRAL COMPOUNDS CONTAINING PYRIDINE
EP3732285A1 (en) 2017-12-28 2020-11-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
KR102881316B1 (ko) 2019-05-13 2025-11-05 노파르티스 아게 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태
WO2021117759A1 (ja) 2019-12-10 2021-06-17 塩野義製薬株式会社 含窒素芳香族複素環式基を有するヒストン脱アセチル化酵素阻害剤
WO2022023447A2 (en) * 2020-07-28 2022-02-03 Jazz Pharmaceuticals Ireland Limited Fused bicyclic raf inhibitors and methods for use thereof
WO2023111996A1 (en) 2021-12-17 2023-06-22 Reglagene Holding, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
US12215102B2 (en) 2023-02-28 2025-02-04 Reglagene, Inc. Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions
CN117567388B (zh) * 2023-11-14 2024-04-16 济南悟通生物科技有限公司 一种2-乙酰基-5-噻唑甲酸的合成方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505193A (ja) * 1996-12-02 2001-04-17 藤沢薬品工業株式会社 ベンズアミド誘導体
JP2004501146A (ja) * 2000-06-19 2004-01-15 フアルマシア・イタリア・エツセ・ピー・アー キナーゼ阻害薬として活性のチオフェン誘導体、その製造方法及びそれを含有する医薬組成物
JP2005511478A (ja) * 2001-04-03 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−置換非アリール複素環アミジル系ｎｍｄａ／ｎｒ２ｂ拮抗薬
JP2005525341A (ja) * 2002-02-18 2005-08-25 アストラゼネカ・アクチエボラーグ 化学化合物
WO2006003378A1 (en) * 2004-07-01 2006-01-12 Astrazeneca Ab Azine-carboxamides as anti-cancer agent
WO2006036266A1 (en) * 2004-07-16 2006-04-06 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as aurora kinase inhibitors
WO2006065703A1 (en) * 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU7095296A (en) * 1995-09-26 1997-04-17 Takeda Chemical Industries Ltd. Phosphorylamides, their preparation and use
CA2240439A1 (en) 1995-12-22 1997-07-03 The Dupont Merck Pharmaceutical Company Novel integrin receptor antagonists
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
US5872136A (en) * 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
AU706150B2 (en) 1996-04-03 1999-06-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5877182A (en) * 1996-09-13 1999-03-02 Merck & Co., Inc. Piperidines promote release of growth hormone
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US6017925A (en) * 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
WO1998042323A1 (en) 1997-03-25 1998-10-01 Takeda Chemical Industries, Ltd. Stabilized urease inhibitor
AU6780398A (en) * 1997-03-28 1998-10-22 Du Pont Merck Pharmaceutical Company, The Heterocyclic integrin inhibitor prodrugs
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
JPH11209366A (ja) 1998-01-23 1999-08-03 Nissan Chem Ind Ltd クロマン誘導体及び心不全治療薬
EP0982030A3 (en) * 1998-08-17 2000-05-10 Pfizer Products Inc. 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
CA2348740A1 (en) * 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
CA2366615A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
EP1171135A4 (en) * 1999-03-10 2002-05-15 Merck & Co Inc 6-AZAINDOL COMPOUNDS AS AN ANTAGONISTS OF THE GONADOTROPIN RELEASING HORMONE
WO2000058300A1 (en) 1999-03-25 2000-10-05 Nissan Chemical Industries, Ltd. Chroman derivatives
US6127382A (en) * 1999-08-16 2000-10-03 Allergan Sales, Inc. Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
WO2001038309A1 (en) 1999-11-24 2001-05-31 Cor Therapeutics, Inc. β-AMINO ACID-, ASPARTIC ACID- AND DIAMINOPROPIONIC-BASED INHIBITORS OF FACTOR Xa
GB0007245D0 (en) 2000-03-24 2000-05-17 Zeneca Ltd Chemical compounds
EP1296678A2 (en) 2000-06-21 2003-04-02 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
MXPA04006260A (es) 2001-12-24 2005-03-31 Astrazeneca Ab Derivados de quinazolina sustituidos como inhibidores de cinasas aurora.
US20040048866A1 (en) * 2002-03-08 2004-03-11 Teodozyj Kolasa Indazole derivatives that are activators of soluble guanylate cyclase
AU2003243318A1 (en) * 2002-05-29 2003-12-19 Millennium Pharmaceuticals, Inc. Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
WO2004000820A2 (en) * 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
CA2491895C (en) * 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1400244A1 (en) * 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
WO2004028526A1 (ja) 2002-09-25 2004-04-08 Santen Pharmaceutical Co., Ltd. ベンズアミド誘導体を有効成分とするリウマチ治療剤
JP2004161716A (ja) 2002-11-15 2004-06-10 Takeda Chem Ind Ltd Ｊｎｋ阻害剤
BRPI0410348A (pt) * 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compostos e usos dos mesmos na modulação de amilóide-beta
JP2004339159A (ja) 2003-05-16 2004-12-02 Sankyo Co Ltd ４−オキソキノリン誘導体を含有する医薬組成物
DE10328999B4 (de) 2003-06-27 2006-08-31 Lanxess Deutschland Gmbh Verfahren zur Herstellung von Metallkomplexpigmenten mit niedriger Dispergierhärte
ES2290754T3 (es) * 2003-07-16 2008-02-16 Janssen Pharmaceutica N.V. Derivados de triazolopirimidina como inhibidores de la glucogeno sintasa cinasa 3.
CA2531232A1 (en) * 2003-07-16 2005-02-10 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
WO2005033086A1 (en) * 2003-09-30 2005-04-14 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1704145B1 (en) 2004-01-12 2012-06-13 YM BioSciences Australia Pty Ltd Selective kinase inhibitors
US20050176733A1 (en) 2004-01-20 2005-08-11 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
EP2332527A3 (en) 2004-10-20 2011-11-16 Resverlogix Corp. Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
EP1841760B1 (en) 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
WO2006076442A2 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
CL2008001933A1 (es) * 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
CA2748274A1 (en) 2008-12-30 2010-07-08 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as raf kinase inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505193A (ja) * 1996-12-02 2001-04-17 藤沢薬品工業株式会社 ベンズアミド誘導体
JP2004501146A (ja) * 2000-06-19 2004-01-15 フアルマシア・イタリア・エツセ・ピー・アー キナーゼ阻害薬として活性のチオフェン誘導体、その製造方法及びそれを含有する医薬組成物
JP2005511478A (ja) * 2001-04-03 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−置換非アリール複素環アミジル系ｎｍｄａ／ｎｒ２ｂ拮抗薬
JP2005525341A (ja) * 2002-02-18 2005-08-25 アストラゼネカ・アクチエボラーグ 化学化合物
WO2006003378A1 (en) * 2004-07-01 2006-01-12 Astrazeneca Ab Azine-carboxamides as anti-cancer agent
WO2006036266A1 (en) * 2004-07-16 2006-04-06 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as aurora kinase inhibitors
WO2006065703A1 (en) * 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106898779A (zh) * 2015-12-21 2017-06-27 斯沃奇集团研究和开发有限公司 用于金属/空气电池的正极和制造该正极的方法
CN106898779B (zh) * 2015-12-21 2020-05-12 斯沃奇集团研究和开发有限公司 用于金属/空气电池的正极和制造该正极的方法
JP2021512861A (ja) * 2018-02-01 2021-05-20 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
JP2022160635A (ja) * 2018-02-01 2022-10-19 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
JP7184383B2 (ja) 2018-02-01 2022-12-06 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
JP7590004B2 (ja) 2018-02-01 2024-11-26 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
JP2023517519A (ja) * 2020-03-02 2023-04-26 シロナックス・リミテッド フェロトーシス阻害剤ジアリールアミンパラアセトアミド類

Also Published As

Publication number Publication date
CN101743242A (zh) 2010-06-16
CA2694284A1 (en) 2009-01-08
WO2009006404A3 (en) 2009-07-30
WO2009006404A2 (en) 2009-01-08
EP2167497A2 (en) 2010-03-31
AU2008273017B2 (en) 2013-10-10
NZ582349A (en) 2012-06-29
AU2008273017C1 (en) 2014-02-13
US7968536B2 (en) 2011-06-28
AU2008273017A1 (en) 2009-01-08
US20090005359A1 (en) 2009-01-01

Similar Documents

Publication Publication Date Title
JP5649445B2 (ja) Ｒａｆキナーゼ阻害剤として有用な化合物
JP2010532381A (ja) Ｒａｆキナーゼ阻害剤として有用な複素環式化合物
JP2012514044A (ja) Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物
US10703748B2 (en) Diazanaphthalen-3-yl carboxamides and preparation and use thereof
KR20210105375A (ko) Cdk 저해제로서의 대환식 화합물, 이의 제조 방법, 및 의약에서의 이의 용도
TW200940544A (en) Inhibitors of PI3 kinase
EP2552922A1 (en) Substituted pyrrolotriazines as protein kinase inhibitors
HK1143357B (en) Pyrimidine derivatives useful as raf kinase inhibitors
HK1143357A (en) Pyrimidine derivatives useful as raf kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120601

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130920

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140312